UPDATE: H.C. Wainwright Starts Monopar Therapeutics (MNPR) at Buy

H.C. Wainwright analyst Sean Lee initiates coverage on Monopar Therapeutics (NASDAQ: MNPR) with a Buy rating and a price target of $9.00.

The analyst comments "Monopar Therapeutics is a clinical-stage biotech company developing novel cancer therapies. The company’s lead product, Validive, is currently being investigated in a Phase 2b/3 study for the treatment of severe oral mucositis (SOM) caused by chemo- and radiotherapy treatments. SOM is one of the most serious complications of cancer treatment and can severely impact patients’ quality of life. It is also a large indication with significant unmet need with an estimated 400,000 patients per year in the U.S. and no specifically approved preventative or curative therapies. The Validive Phase 2b/3 study is expected to report interim results in 1H22, which we believe could be a major catalyst for the stock. Currently, we project Validive to reach the market in 2025 and achieve risk-adjusted revenues of $111M by 2033."

For an analyst ratings summary and ratings history on Monopar Therapeutics click here. For more ratings news on Monopar Therapeutics click here.

Shares of Monopar Therapeutics closed at $4.80 yesterday.

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral